Ramosetron, Aprepitant, and Dexamethasone Versus Palonosetron, Aprepitant, and Dexamethasone
Status:
Completed
Trial end date:
2018-05-08
Target enrollment:
Participant gender:
Summary
The purpose of this study is to compare the anti-emetic effect of ramosetron plus aprepitant
and dexamethasone with palonosetron plus aprepitant and dexamethasone in patients receiving
highly emetogenic chemotherapy.
Phase:
Phase 4
Details
Lead Sponsor:
Kangdong Sacred Heart Hospital
Collaborators:
Astellas Pharma Korea, Inc. The Catholic University of Korea